Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study unconfirmed

Story checked

Adalvo expands biosimilars portfolio through acquisition of romiplostim biosimilar program from Enzene (opens in a new tab)

news-medical.net · 2026-10-28

Short answerEvidenceSource

Short answer

Source study unconfirmed

Study not confirmed.

The search did not establish a source study for this article. Its claims remain unverified; this does not mean they are incorrect.

15 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

No single source study could be confirmed.

The search identified related research but did not establish a single source study. Related papers are provided for context, not as verification of the article's claims.

View article claims
3

Search result

Source study unconfirmed.

The search identified related research but did not establish a single source study. Related papers are provided for context, not as verification of the article's claims.

The literature search

15 candidate papers

Studies identified during the search

These papers appeared in the search for the story’s source. None was confirmed as a direct match. Inclusion here does not mean a paper supports or contradicts the story, or that its full text was reviewed.

Show 11 more search results
Then inspect each claim

Evidence layer

Claim by claim

The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.

Claim 1 of 5Not checkedAdalvo announced the acquisition of a romiplostim biosimilar program referencing Nplate® from Enzene.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 2 of 5Not checkedThe transaction is presented as strengthening Adalvo’s biosimilars portfolio and accelerating its expansion into complex biological medicines.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 3 of 5Not checkedThe acquired program references Nplate® (romiplostim), which the article says is indicated for adult and chronic pediatric immune thrombocytopenia (ITP).View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 4 of 5Not checkedEnzene is said to continue as the development and manufacturing partner, including support for regulatory filings with the US FDA, the European Medicines Agency and other authorities, and to supply the product from its GMP-approved facilities in Pune, India.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 5 of 5Not checkedThe article says the reference product generated approximately USD 1.5 billion in global sales in 2025, framing the program as a significant global opportunity.View evidenceHide evidence

As statedapproximately USD 1.5 billion in global sales in 2025

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Finally, the search trail

Method layer

Study not confirmed.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results

Candidate papers, not confirmed sources.

PubMed, Europe PMC, Crossref · 15 candidate papers

Candidate

FDA approves romiplostim for pediatric patients with immune thrombocytopenia

Case Medical Research · 2018 · Crossref

Source (opens in a new tab)

Explore all search results